patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_630904 | REC_0008001 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.9 | 70 | male | 2 | 14 | 5.1 | 1 | entrectinib 600 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:58.817776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699474 | REC_0008002 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.5 | 82 | female | 2 | 16 | 4.3 | 5 | pembrolizumab 200 mg q3w | 10.7 | true | MSS | 2026-03-15T05:35:58.818017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220648 | REC_0008003 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 10.5 | 71 | female | 2 | 12 | 4.7 | 2 | pembrolizumab 200 mg q3w | 22.2 | true | MSS | 2026-03-15T05:35:58.818264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846743 | REC_0008004 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 11.1 | 72 | female | 2 | 27 | 6.9 | 2 | osimertinib 80 mg daily | 30.4 | false | MSS | 2026-03-15T05:35:58.818510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769251 | REC_0008005 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.3 | 69 | female | 0 | 9 | 6.8 | 4 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:58.818764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295625 | REC_0008006 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.2 | 72 | female | 3 | 14 | 6.3 | 1 | alectinib 600 mg BID | 35.4 | false | MSS | 2026-03-15T05:35:58.819021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498251 | REC_0008007 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.3 | 75 | female | 1 | 73 | 4.8 | 4 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.819272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586724 | REC_0008008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9 | 55 | male | 1 | 17 | 5.1 | 6 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.819533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788531 | REC_0008009 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 14.7 | 74 | female | 1 | 12 | 5.7 | 1 | osimertinib 80 mg daily | 23.7 | false | MSS | 2026-03-15T05:35:58.819929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744015 | REC_0008010 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.4 | 78 | female | 3 | 16 | 5.3 | 6 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.820258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148639 | REC_0008011 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7.8 | 67 | female | 0 | 21 | 3.7 | 6 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:35:58.820539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679034 | REC_0008012 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.9 | 73 | female | 1 | 45 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:58.820795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557461 | REC_0008013 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.1 | 52 | female | 0 | 20 | 5.3 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.821063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711715 | REC_0008014 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 18 | 72 | male | 1 | 18 | 7.9 | 1 | sotorasib 960 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:58.821323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221284 | REC_0008015 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.8 | 57 | male | 1 | 7 | 5.3 | 6 | pembrolizumab 200 mg q3w | 10.4 | false | MSS | 2026-03-15T05:35:58.821575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810857 | REC_0008016 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 17.3 | 81 | female | 1 | 10 | 5.5 | 7 | sotorasib 960 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:58.821823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387120 | REC_0008017 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.4 | 66 | female | 1 | 22 | 7.1 | 2 | osimertinib 80 mg daily | 28.1 | false | MSI-H | 2026-03-15T05:35:58.822074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258320 | REC_0008018 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.6 | 72 | female | 2 | 54 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.2 | false | MSS | 2026-03-15T05:35:58.822320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119419 | REC_0008019 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.8 | 71 | female | 2 | 11 | 5 | 1 | sotorasib 960 mg daily | 22 | false | MSI-H | 2026-03-15T05:35:58.822571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645042 | REC_0008020 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.8 | 69 | female | 0 | 60 | 3.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.4 | false | MSS | 2026-03-15T05:35:58.822819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377524 | REC_0008021 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 10.4 | 68 | female | 0 | 18 | 7.1 | 1 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:58.823066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802943 | REC_0008022 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.3 | 73 | female | 2 | 16 | 5.8 | 1 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:35:58.823430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410082 | REC_0008023 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 10.8 | 66 | female | 0 | 11 | 7.4 | 1 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.823689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350488 | REC_0008024 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.2 | 55 | female | 1 | 20 | 5.5 | 8 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.823941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685996 | REC_0008025 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 5.8 | 85 | male | 2 | 56 | 4.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 43.6 | true | MSS | 2026-03-15T05:35:58.824240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343945 | REC_0008026 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 11.2 | 62 | male | 1 | 29 | 5 | 7 | pembrolizumab 200 mg q3w | 7.3 | true | MSI-H | 2026-03-15T05:35:58.824496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339516 | REC_0008027 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.2 | 59 | female | 1 | 22 | 6.1 | 1 | alectinib 600 mg BID | 18.9 | false | MSS | 2026-03-15T05:35:58.824746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467249 | REC_0008028 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 7.8 | 69 | female | 0 | 20 | 6 | 2 | sotorasib 960 mg daily | 21.5 | true | MSS | 2026-03-15T05:35:58.824988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985616 | REC_0008029 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.8 | 64 | male | 0 | 67 | 7.6 | 6 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:35:58.825226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345329 | REC_0008030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 6 | 70 | male | 2 | 14 | 4.7 | 4 | entrectinib 600 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:58.825464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265977 | REC_0008031 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 9.9 | 72 | female | 1 | 23 | 3.2 | 2 | sotorasib 960 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:58.825699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481192 | REC_0008032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.1 | 78 | male | 1 | 9 | 5.2 | 6 | osimertinib 80 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:58.825935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768648 | REC_0008033 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 6.4 | 70 | male | 2 | 24 | 6.2 | 2 | alectinib 600 mg BID | 26.6 | false | MSS | 2026-03-15T05:35:58.826168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105977 | REC_0008034 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 14.4 | 73 | male | 3 | 3 | 6.5 | 0 | sotorasib 960 mg daily | 48.1 | false | MSS | 2026-03-15T05:35:58.826402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897114 | REC_0008035 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 8.6 | 67 | male | 0 | 8 | 5 | 2 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.826733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657617 | REC_0008036 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.4 | 65 | female | 1 | 13 | 4.2 | 6 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:58.826969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257389 | REC_0008037 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.1 | 72 | female | 1 | 13 | 4.7 | 1 | osimertinib 80 mg daily | 39.3 | false | MSS | 2026-03-15T05:35:58.827202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827165 | REC_0008038 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.7 | 53 | female | 0 | 9 | 6.7 | 6 | sotorasib 960 mg daily | 6.1 | true | MSI-H | 2026-03-15T05:35:58.827438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722658 | REC_0008039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 15.4 | 90 | female | 2 | 18 | 7.1 | 7 | entrectinib 600 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.827672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159158 | REC_0008040 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12 | 72 | female | 1 | 9 | 5.4 | 2 | osimertinib 80 mg daily | 17.5 | false | MSI-H | 2026-03-15T05:35:58.827904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735558 | REC_0008041 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.7 | 74 | female | 1 | 19 | 6.3 | 4 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.828176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663684 | REC_0008042 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 8.7 | 67 | female | 0 | 19 | 7.2 | 4 | osimertinib 80 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:58.828412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265591 | REC_0008043 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.9 | 70 | female | 2 | 18 | 3.6 | 5 | entrectinib 600 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.828644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717805 | REC_0008044 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 27 | 5.6 | 57 | female | 1 | 78 | 5 | 0 | pembrolizumab 200 mg q3w | 23.2 | false | MSS | 2026-03-15T05:35:58.828879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702826 | REC_0008045 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.4 | 70 | female | 1 | 75 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:35:58.829105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675652 | REC_0008046 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.3 | 54 | female | 0 | 70 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 27.7 | true | MSS | 2026-03-15T05:35:58.829336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132758 | REC_0008047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 14.8 | 77 | female | 1 | 19 | 3.8 | 7 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:58.829569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919188 | REC_0008048 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 18.6 | 74 | female | 1 | 12 | 3.5 | 7 | alectinib 600 mg BID | 15.9 | false | MSI-H | 2026-03-15T05:35:58.829849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548854 | REC_0008049 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 13.6 | 67 | male | 0 | 13 | 7.3 | 7 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.830089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406280 | REC_0008050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.4 | 68 | female | 1 | 9 | 6 | 6 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:58.830325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723120 | REC_0008051 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 7.7 | 63 | female | 1 | 10 | 4 | 4 | sotorasib 960 mg daily | 5.1 | false | MSS | 2026-03-15T05:35:58.830557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275830 | REC_0008052 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.9 | 76 | female | 2 | 2 | 3.9 | 5 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.830793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546036 | REC_0008053 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.8 | 87 | female | 1 | 15 | 7.1 | 1 | osimertinib 80 mg daily | 21.2 | false | MSI-H | 2026-03-15T05:35:58.831025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961020 | REC_0008054 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.6 | 65 | female | 1 | 14 | 4.3 | 6 | pembrolizumab 200 mg q3w | 9.7 | true | MSS | 2026-03-15T05:35:58.831261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360922 | REC_0008055 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.2 | 60 | male | 1 | 40 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.9 | true | MSS | 2026-03-15T05:35:58.831493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229139 | REC_0008056 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 4.3 | 59 | female | 0 | 19 | 4.6 | 2 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:58.831727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419534 | REC_0008057 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.5 | 76 | female | 1 | 22 | 3.2 | 2 | alectinib 600 mg BID | 6.3 | true | MSS | 2026-03-15T05:35:58.831959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994453 | REC_0008058 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 15.1 | 75 | female | 3 | 8 | 5.2 | 1 | osimertinib 80 mg daily | 24.3 | false | MSS | 2026-03-15T05:35:58.832247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400517 | REC_0008059 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.2 | 71 | female | 3 | 13 | 4.5 | 5 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:58.832485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890728 | REC_0008060 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 3.8 | 62 | male | 0 | 10 | 4 | 2 | pembrolizumab 200 mg q3w | 27.2 | true | MSS | 2026-03-15T05:35:58.832731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752342 | REC_0008061 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 9.9 | 67 | female | 0 | 9 | 5.2 | 2 | entrectinib 600 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:58.833006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371382 | REC_0008062 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15.8 | 63 | male | 1 | 18 | 5.9 | 8 | sotorasib 960 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.833246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927855 | REC_0008063 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.2 | 61 | male | 1 | 18 | 5.1 | 6 | alectinib 600 mg BID | 7 | true | MSI-H | 2026-03-15T05:35:58.833485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361979 | REC_0008064 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.2 | 56 | male | 0 | 8 | 5.9 | 1 | entrectinib 600 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.833720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117951 | REC_0008065 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 12.7 | 70 | female | 2 | 13 | 7.8 | 2 | entrectinib 600 mg daily | 22.7 | false | MSI-H | 2026-03-15T05:35:58.833955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209680 | REC_0008066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.5 | 69 | female | 0 | 57 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:58.834185+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816770 | REC_0008067 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 16.2 | 68 | male | 0 | 25 | 4.4 | 0 | osimertinib 80 mg daily | 59.9 | true | MSI-H | 2026-03-15T05:35:58.834423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457053 | REC_0008068 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.7 | 65 | male | 1 | 46 | 4.9 | 5 | pembrolizumab 200 mg q3w | 13.4 | false | MSS | 2026-03-15T05:35:58.834653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134336 | REC_0008069 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 7.2 | 69 | female | 1 | 17 | 3.6 | 4 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:58.834881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327072 | REC_0008070 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.2 | 68 | female | 1 | 14 | 8 | 7 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:58.835111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644738 | REC_0008071 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 11.3 | 65 | male | 0 | 12 | 4.8 | 1 | entrectinib 600 mg daily | 22.7 | true | MSS | 2026-03-15T05:35:58.835345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593757 | REC_0008072 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 9.6 | 77 | female | 1 | 10 | 5 | 2 | pembrolizumab 200 mg q3w | 22.6 | true | MSS | 2026-03-15T05:35:58.835573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785827 | REC_0008073 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.6 | 55 | male | 0 | 12 | 3.3 | 6 | alectinib 600 mg BID | 8.6 | false | MSI-H | 2026-03-15T05:35:58.835804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457132 | REC_0008074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 16.1 | 62 | male | 0 | 7 | 3.5 | 6 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.836188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918823 | REC_0008075 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.6 | 60 | female | 0 | 11 | 6.9 | 5 | entrectinib 600 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:58.836440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757735 | REC_0008076 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.7 | 66 | female | 0 | 24 | 6.9 | 2 | osimertinib 80 mg daily | 20.4 | true | MSS | 2026-03-15T05:35:58.836698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344385 | REC_0008077 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.8 | 67 | female | 1 | 10 | 4.1 | 2 | alectinib 600 mg BID | 7.7 | true | MSS | 2026-03-15T05:35:58.836946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427675 | REC_0008078 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 8.9 | 76 | female | 1 | 10 | 5.5 | 7 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.837176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532710 | REC_0008079 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 9.2 | 66 | female | 1 | 14 | 5.3 | 8 | sotorasib 960 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:58.837413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699424 | REC_0008080 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.6 | 83 | male | 3 | 81 | 5.3 | 7 | pembrolizumab 200 mg q3w | 4.6 | true | MSS | 2026-03-15T05:35:58.837650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819534 | REC_0008081 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 14.9 | 73 | male | 1 | 5 | 4.7 | 1 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:35:58.837897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440901 | REC_0008082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.4 | 58 | female | 1 | 14 | 2.5 | 8 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:58.838143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614161 | REC_0008083 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 8.8 | 70 | male | 2 | 9 | 5.9 | 1 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.838392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250387 | REC_0008084 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 12.2 | 67 | female | 0 | 6 | 5 | 6 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:58.838643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457282 | REC_0008085 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 13 | 42 | female | 0 | 7 | 5.4 | 6 | entrectinib 600 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.838897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909641 | REC_0008086 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 17 | 9.8 | 76 | female | 0 | 18 | 5.7 | 0 | pembrolizumab 200 mg q3w | 33.4 | false | MSS | 2026-03-15T05:35:58.839137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168402 | REC_0008087 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 14.3 | 67 | female | 1 | 12 | 6.3 | 1 | entrectinib 600 mg daily | 25.6 | false | MSS | 2026-03-15T05:35:58.839505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916110 | REC_0008088 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.7 | 67 | female | 0 | 80 | 5.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:35:58.839754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429146 | REC_0008089 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.7 | 71 | female | 1 | 15 | 4.5 | 5 | sotorasib 960 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:58.839987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772800 | REC_0008090 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 4.9 | 72 | female | 3 | 15 | 6.2 | 4 | alectinib 600 mg BID | 4.5 | false | MSS | 2026-03-15T05:35:58.840322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450541 | REC_0008091 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 5.2 | 77 | female | 3 | 6 | 5.2 | 5 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.840564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406603 | REC_0008092 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 18.3 | 62 | female | 0 | 10 | 6.2 | 6 | pembrolizumab 200 mg q3w | 11.6 | false | MSI-H | 2026-03-15T05:35:58.840801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128672 | REC_0008093 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 16.4 | 65 | male | 1 | 17 | 5.2 | 2 | osimertinib 80 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:58.841037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132601 | REC_0008094 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 7.7 | 62 | female | 0 | 4 | 4.6 | 1 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:35:58.841269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912580 | REC_0008095 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 18 | 6.3 | 63 | male | 0 | 32 | 2.6 | 3 | pembrolizumab 200 mg q3w | 22.1 | false | MSS | 2026-03-15T05:35:58.841503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533103 | REC_0008096 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 14.4 | 65 | female | 1 | 18 | 3.7 | 1 | sotorasib 960 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:58.841739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855570 | REC_0008097 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 58 | male | 0 | 13 | 6 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.841974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305994 | REC_0008098 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.2 | 58 | male | 1 | 34 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:58.842205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729380 | REC_0008099 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.6 | 74 | female | 1 | 6 | 6.6 | 3 | sotorasib 960 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:58.842432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171727 | REC_0008100 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 6.6 | 57 | male | 1 | 0 | 2.6 | 5 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.842728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.